NCCN Brings Tailored Cancer Guidelines to the Philippines in Global Push

The National Comprehensive Cancer Network, the United States-based alliance of leading academic cancer centers, has taken one of its most significant international steps yet, announcing a sweeping program to adapt its clinical practice guidelines for the Philippines. The announcement was made during the network’s participation in two major oncology gatherings on opposite sides of the world: the annual global meeting of the International Gynecologic Cancer Society in Montreal, held October 1 through 3, and a joint summit organized by the Philippine Society of Medical Oncology, the Philippine Department of Health, and NCCN during the PSMO annual scientific meeting in Manila, held October 6 through 9. Together, these meetings underscored a growing recognition that evidence-based cancer treatment recommendations cannot simply be exported from one health system to another without careful, regionally grounded adaptation.

At the heart of the initiative are new International Adaptations of the NCCN Clinical Practice Guidelines in Oncology, a family of treatment recommendations widely regarded as among the most thorough and frequently updated clinical standards in medicine. The Philippine adaptations are being developed in close collaboration with the Philippine Society of Medical Oncology and, for gynecologic malignancies, with the Society of Gynecological Oncologists of the Philippines, with additional support from the International Gynecologic Cancer Society. The planned disease coverage is broad and deliberately aligned with the country’s most pressing cancer burdens: B-cell lymphomas, breast cancer, colon cancer, hepatocellular carcinoma, lung cancer, prostate cancer, and rectal cancer will be adapted with PSMO, while cervical, ovarian, and uterine cancers will be adapted with SGOP and IGCS. Once completed, all of the NCCN Guidelines for the Philippines will be available free of charge through the network’s global portal in the months ahead.

Crystal S. Denlinger, MD, Chief Executive Officer of NCCN, framed the collaboration as part of a broader commitment to equity in cancer care. “Our joint efforts in the Philippines and beyond reflect a shared commitment to improving access to appropriate cancer care, reducing disparities in treatment, and strengthening oncology practice through proven guidance,” she said. “By working with regional experts to regionally tailor NCCN’s guidelines for use in the Philippines, we combine our expertise to provide evidence-based recommendations that are more meaningful and usable for regional clinical settings. Through this global collaboration, we will create opportunities to grow our efforts with providers worldwide to develop practical tools that serve communities across the globe.”

The technical logic behind international adaptations is straightforward but demanding. Clinical guidelines encode not only biomedical evidence but also assumptions about available diagnostics, drug formularies, referral pathways, regulatory approvals, and health system financing. A recommendation that is feasible at a comprehensive cancer center in the United States may be impractical in a provincial hospital in the Philippines, where imaging capacity, pathology services, or targeted therapies may be limited or differently regulated. Adaptation therefore involves panels of local experts who review each recommendation against the realities of regional practice, adjusting where necessary while preserving the evidence-based core. The result is intended to be a document that clinicians can actually follow, rather than an aspirational standard that sits unused on a shelf.

The Manila summit, held on October 6, went beyond the mechanics of guideline writing to address a harder question: how localized recommendations become embedded in national health policy. PSMO, the Department of Health, and NCCN convened a high-level meeting focused on strategies to integrate the adapted guidelines into national programs under the National Integrated Cancer Control Act, the Philippine legislation that established a coordinated framework for cancer prevention, treatment, and survivorship. Highlighting global implementation models, NCCN was joined by Professor Jacek Jassem of the Medical University of Gdansk, who shared insights from Poland’s successful experience in developing and implementing the NCCN Guidelines for Poland, an example often cited as proof that a national health system can adopt and operationalize adapted guidelines at scale.

For the Philippine Society of Medical Oncology, the project represents a chance to codify local expertise within an internationally trusted framework. “NCCN Guidelines are the most reliable tools that cancer care providers use worldwide to improve prevention, treatment, and outcomes for people with cancer. Developing regionally tailored guidelines alongside NCCN and international experts allows us to seamlessly combine global clinical standards with our local expertise and regulatory environment,” said Hiyasmin A. Alejandro, MD, PSMO Vice President and Co-Lead of the NCCN adaptation project in the Philippines. “This collaboration directly strengthens our medical oncology practice, empowering Filipino healthcare providers to deliver more consistent, high-quality, and equitable care customized to the realities and regulations here in the Philippines.”

The gynecologic cancer component carries particular weight in a country where cervical, ovarian, and uterine malignancies remain significant causes of cancer-related death among women, and where access to subspecialty care varies dramatically between metropolitan Manila and more remote regions. Dr. Doris Benavides, immediate past president of the Society of Gynecological Oncologists of the Philippines, emphasized that adaptation is a two-way process rather than a simple translation exercise. “True collaboration means co-creating solutions that meet the specific needs of our patients,” she said. “By adapting the NCCN Guidelines for cervical, uterine, and ovarian cancers to the Philippine setting, we’re giving our gynecologic oncologists evidence-based recommendations grounded in the realities of local practice in various regions of the country. This important initiative will raise the standard of care and improve long-term health outcomes for Filipino women and their families. We are grateful to NCCN and IGCS for their commitment to global collaboration. This partnership lets Filipino specialists contribute local insight while benefiting from one of the world’s most trusted oncology guideline frameworks.”

The Philippine program is also serving as a template for further expansion. Building on the gynecologic cancer initiative, NCCN recently signed a new Memorandum of Understanding with the International Gynecologic Cancer Society to explore the implementation of tailored gynecologic cancer guidelines in other regions. “IGCS is committed to improving gynecologic cancer care worldwide through education, training, and awareness,” said Mary Eiken, MS, CEO of IGCS. “Our Strategic Alliance Partner Program brings together leaders and members of gynecologic oncology organizations across specialties and regions around the world. We’re excited to collaborate with NCCN to help translate NCCN Guidelines into practice for gynecologic cancer patients.” The MOU signals that the co-creation model piloted in Manila, in which national societies contribute clinical and regulatory insight while NCCN contributes its evidence-review infrastructure, could be replicated wherever professional societies and health ministries are prepared to invest in adaptation.

The scale of NCCN’s existing international footprint gives the Philippine project considerable leverage. There are currently more than 90 international adaptations of the NCCN Guidelines and more than 180 different translations across numerous languages, a library that allows clinicians in widely varying settings to consult recommendations calibrated to their own circumstances. Each adaptation undergoes the same underlying discipline: systematic review of the evidence, expert consensus, and frequent updates as new data emerge, followed by regional modification for feasibility and applicability. Because the Philippine adaptations will be freely accessible online, they have the potential to reach not only specialists in tertiary centers but also the general practitioners and community oncologists who manage the majority of cancer patients in the country.

What emerges from the Montreal and Manila meetings is a picture of cancer care standardization as a genuinely global, collaborative enterprise rather than a one-directional export of American clinical doctrine. The Philippine adaptations, spanning seven disease types with PSMO and three gynecologic cancers with SGOP and IGCS, will test whether locally co-created guidelines can be woven into national policy under the National Integrated Cancer Control Act and sustained through the country’s health programs. If the Polish experience is any guide, the combination of professional society leadership, ministerial support, and an internationally recognized evidence framework can produce measurable improvements in consistency and quality of care. For Filipino patients, the practical promise is concrete: treatment recommendations that reflect both the best available global evidence and the specific realities of the hospitals, regulations, and resources where they are actually treated.

Subject of Research: International adaptation of NCCN clinical practice guidelines for cancer treatment in the Philippines

Article Title: NCCN highlights collaborations to improve global cancer outcomes during meetings in North America and Asia

Article References: NCCN highlights collaborations to improve global cancer outcomes during meetings in North America and Asia. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: NCCN, cancer guidelines, Philippines, gynecologic oncology, PSMO, IGCS, SGOP, international adaptations, health policy, NICCA, cancer care equity, oncology